# Wegovy vs Ozempic: what actually differs between the two semaglutides > Source: https://peptidewellnessusa.com/peptides/compare/wegovy-vs-ozempic/ > Compare · GLP-1 > By PeptideWellness Editorial Team · Medically reviewed by Ksenia Petrushkina, PA-C, MPAS · Updated November 11, 2026 · 6 min read Both are semaglutide from Novo Nordisk. Ozempic is the diabetes product and stops at 2 mg a week; Wegovy is the weight product and goes to 2.4 mg, with a 7.2 mg strength above that and, since December 2025, a daily tablet. The approved uses, the doses, the trials and what each costs. Both are semaglutide, made by Novo Nordisk. The difference is what each is approved for, and the dose that follows. Ozempic is the type 2 diabetes product. Its weekly injection goes up to 2 mg [2]. Wegovy is the weight product. Its weekly injection goes up to 2.4 mg, with a 7.2 mg strength added for people who need more, and since late 2025 there is also a Wegovy tablet taken daily [1]. People lose weight on both, because it is the same drug, but only one of them has the weight-loss trials and the weight-loss label. ## Approved uses | | Wegovy | Ozempic | | --- | --- | --- | | Weight | Yes, in adults and children 12 and over | No | | Type 2 diabetes | No | Yes | | Heart-risk reduction | Yes, in adults with heart disease and obesity or overweight | Yes, in adults with type 2 diabetes and established heart disease | | Kidney | No | Yes, to slow kidney decline in type 2 diabetes with chronic kidney disease | | Liver | Yes, for MASH with moderate to advanced fibrosis, under accelerated approval | No | Sources: the two labels [1][2]. Prescribing Ozempic for weight is off-label. A prescriber may do it, and it is the usual reason an insurer refuses to pay, because the plan's weight-drug rules and its diabetes-drug rules are different. ## Doses and forms **Ozempic.** Start at 0.25 mg once a week for four weeks, then 0.5 mg, then 1 mg, then 2 mg, each step after at least four weeks and only if more blood-sugar control is needed. The pens hold several weekly doses; there are also single-dose prefilled syringes at 0.25, 0.5 and 1 mg [2]. **Wegovy.** Start at 0.25 mg and step up every four weeks to the 2.4 mg maintenance dose. The label also allows an increase to 7.2 mg after at least four weeks at 2.4 mg. There is also a daily tablet at 1.5, 4, 9 and 25 mg, and a switch between them: one week after the last 2.4 mg injection you can start the 25 mg tablet, and the day after your last tablet you can start the 2.4 mg injection [1]. A detail that trips people up: Ozempic now also has a tablet, sold under both the Ozempic and Rybelsus names, and those are diabetes products, not weight products. They are swallowed on an empty stomach with no more than four ounces of water, 30 minutes before anything else [3]. The Wegovy tablet is taken the same way [1]. Our page on [sublingual semaglutide](https://peptidewellnessusa.com/learn/sublingual-semaglutide/) covers the compounded versions that are none of these. ## What the trials measured **Wegovy's trials measured weight.** In the main 68-week trial in adults with obesity or overweight with a weight-related condition, average weight fell 14.9% against 2.4% on placebo [1]. The 25 mg tablet reached 13.6% against 2.4% over 64 weeks [1]. SELECT, in adults with heart disease and excess weight but not diabetes, found 6.5% of people on Wegovy had a heart death, heart attack or stroke against 8% on placebo, a hazard ratio of 0.80 [1]. **Ozempic's trials measured blood sugar, hearts and kidneys.** SUSTAIN 6 followed 3,297 adults with type 2 diabetes and heart disease for at least two years: 6.6% on semaglutide had a major cardiac event against 8.9% on placebo, a hazard ratio of 0.74 [2]. FLOW followed 3,533 adults with type 2 diabetes and chronic kidney disease for a median of 41 months and found fewer kidney failures and deaths, a hazard ratio of 0.76 for the composite endpoint [2]. Weight loss appears in the diabetes trials too: about 4.8 kg on 1 mg over 56 weeks in one of them, against 2 kg on a comparator drug [2]. Those numbers are not comparable to Wegovy's. Different populations, different doses, different measurements. ## Side effects The same molecule, the same list, at rates that track the dose and the population. In the Wegovy weight trials nausea affected 44% against 16% on placebo, diarrhea 30%, vomiting 24%, constipation 24% [1]. In Ozempic's diabetes trials nausea was 15.8% at 0.5 mg and 20.3% at 1 mg, against 6.1% [2]. Both carry the same boxed warning about thyroid C-cell tumors seen in rodents, and the same warnings for pancreatitis, gallbladder disease, kidney injury from dehydration, severe stomach problems, allergic reactions, low blood sugar, worsening diabetic eye disease and food entering the lungs under anesthesia [1][2]. Our [GLP-1 side effects](https://peptidewellnessusa.com/learn/glp-1-side-effects/) page has the full tables. ## Cost Different coverage rules, different cash prices. Novo sells Wegovy direct: for patients new to the offer, $199 a month at the 0.25 and 0.5 mg pens for two fills through 31 December 2026, then $349 a month for any dose up to 2.4 mg, or $399 for the 7.2 mg strength. The tablets run $149 to $299 a month depending on dose [4]. With commercial insurance that covers it, the savings offer brings Wegovy to as little as $25 a month, with government plans excluded [4]. The Medicare GLP-1 Bridge covers Wegovy, injection or tablets, at $50 a month for eligible Part D members until the end of 2027 [5]. It does not cover Ozempic, which Part D plans generally cover already as a diabetes drug. [How to get a GLP-1](https://peptidewellnessusa.com/learn/how-to-get-a-glp-1/) goes through the routes, and [what's in a GLP-1 price](https://peptidewellnessusa.com/learn/whats-in-a-glp1-price/) through the conditions attached to the advertised numbers. ## Which one The diagnosis decides. Type 2 diabetes points to Ozempic, whose label carries the diabetes, heart and kidney data and whose coverage follows diabetes rules. Weight, with or without heart disease, points to Wegovy, whose label carries the weight and heart data at the higher dose. If what you want is the strongest weight result rather than this particular molecule, the comparison that matters is [tirzepatide vs semaglutide](https://peptidewellnessusa.com/peptides/compare/tirzepatide-vs-semaglutide/). ## Frequently asked ### Is Wegovy the same as Ozempic? Same molecule, semaglutide. Different approved uses and different maximum doses: 2.4 mg a week for Wegovy, 2 mg for Ozempic [1][2]. ### Can I take Ozempic for weight loss? A prescriber can write it off-label, and people do lose weight on it. The weight trials and the weight label belong to Wegovy, and insurance usually follows the label [1][2]. ### Which is better for weight loss? Wegovy, by dose. It reaches 2.4 mg a week, where average weight loss was 14.9% over 68 weeks, and there is a 7.2 mg strength above that [1]. Ozempic stops at 2 mg. ### Is Wegovy stronger than Ozempic? It goes higher. The maintenance dose is 2.4 mg against Ozempic's maximum of 2 mg, with a 7.2 mg option on the Wegovy label [1][2]. ### Does Medicare cover Wegovy or Ozempic? Part D generally covers Ozempic as a diabetes drug. For weight, the Medicare GLP-1 Bridge covers Wegovy at $50 a month until 31 December 2027, if you qualify [5]. ### What about the Wegovy and Ozempic tablets? The Wegovy tablet, up to 25 mg daily, is for weight. The Ozempic and Rybelsus tablets are for type 2 diabetes. All are swallowed on an empty stomach, 30 minutes before anything else [1][3]. ## References 1. [FDA. Wegovy (semaglutide) injection and tablets, prescribing information, revised June 2026: sections 1, 2, 3, 6.1 and 14. DailyMed, read 10 November 2026.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) 2. [FDA. Ozempic (semaglutide) injection, prescribing information, effective 1 June 2026: sections 1, 2, 3, 6.1 and 14. DailyMed, read 10 November 2026.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79) 3. [FDA. Rybelsus and Ozempic (oral semaglutide) tablets, prescribing information, effective 30 January 2026: sections 1, 2 and 3. DailyMed, read 10 November 2026.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98) 4. [NovoCare. Wegovy cost, coverage and savings. Read 10 November 2026.](https://www.novocare.com/patient/medicines/wegovy.html) 5. [Medicare.gov. Weight loss drugs: the Medicare GLP-1 Bridge. Read 10 November 2026.](https://www.medicare.gov/coverage/weight-loss-drugs) ## Medical disclaimer This page is informational and is not medical advice. It compares two approved labels for the same molecule; it cannot tell you whether semaglutide is appropriate for you. Both carry a boxed warning for thyroid C-cell tumors and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Which product, which dose and whether to start are decisions for a prescriber.